Aberrant signalling by protein kinase CK2 in imatinib‐resistant chronic myeloid leukaemia cells: Biochemical evidence and therapeutic perspectives

Chronic myeloid leukaemia (CML) is driven by the fusion protein Bcr‐Abl, a constitutively active tyrosine kinase playing a crucial role in initiation and maintenance of CML phenotype. Despite the great efficacy of the Bcr‐Abl‐specific inhibitor imatinib, resistance to this drug is recognized as a ma...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Main Authors: Borgo, Christian, Cesaro, Luca, Salizzato, Valentina, Ruzzene, Maria, Massimino, Maria Lina, Pinna, Lorenzo A., Donella-Deana, Arianna
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2013
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528438/
https://ncbi.nlm.nih.gov/pubmed/24012109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2013.08.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados